Page 10 - Johan Dalsgaard News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF - Webinar will be held today at 15:00 CET (9:00 am EST) - Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program News provided by Share this article GOTHENBURG, Sweden, May 4, 2021 /PRNewswire/ --  Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics AB for the develo...

Share this article GOTHENBURG, Sweden, April 20, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announced that it will host a key opinion leader (KOL) webinar on C21, the company's lead asset for the treatment of COVID-19, on Wednesday, April 28, 2021 at 14:00 CET (8 am EST). The event will feature a presentation by KOL Professor Maureen Horton, M.D., Johns Hopkins University School of Medicine, who will discuss the current treatment landscap...

Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease News provided by Share this article GOTHENBURG, Sweden, March 11, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces top line data from a phase II study of its oral angiotensin II type 2 receptor (AT2R) agonist C21 in patients with systemic sclerosis and Raynaud's phenomenon. In this mechanistic 12-person single-dose study, C21 did not reach the predefined...

Vicore Pharma intends to carry out a directed share issue GOTHENBURG, Sweden, Feb. 9, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company") today announces its intention to carry out a directed share issue corresponding to approximately SEK 300 million to institutional investors through an accelerated bookbuilding procedure (the "Directed New Share Issue"). The Directed New Share Issue is intended to be carried out through an accelerated bookbuilding procedure which commences immediately after announcement of this press release. Pricing and allocation of the...

Share this article GOTHENBURG, Sweden, Feb. 1, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today published data from the phase II study ATTRACT online and submitted it to a peer reviewed journal. The results show restoration of lung function in COVID-19 on top of corticosteroids and remdesivir with the company's oral drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic. With close to 100 million registered cases and 2 million deat...